Meriofert

Luteinising hormone (human), Follicle‑stimulating hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is employed in assisted reproductive protocols to address infertility caused by anovulation, to stimulate controlled ovarian stimulation, and to treat male hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and procurement teams worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support global distribution and import compliance.

Meriofert, a gonadotropin used in reproductive endocrinology, is indicated for several infertility‑related conditions. - Infertility due to anovulation: facilitates follicular development and ovulation to improve chances of conception. - Controlled ovarian stimulation: supports multiple follicle growth for in‑vitro fertilisation cycles. - Male hypogonadotropic hypogonadism: stimulates endogenous testosterone production and spermatogenesis. - Assisted reproductive technology cycles: used in combination protocols to optimise oocyte retrieval and embryo quality.

Adverse reactions reported with Meriofert are related to its hormonal activity and injection site.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache occurring after administration. - Nausea: mild gastrointestinal upset. - Abdominal bloating: sensation of fullness or mild distension. - Ovarian hyperstimulation symptoms: mild abdominal discomfort, mild weight gain.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe abdominal pain, ascites, thromboembolism. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Allergic reaction: rash, urticaria, or anaphylaxis. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Ectopic pregnancy: implantation outside the uterus.

When using Meriofert, careful monitoring and patient assessment are essential. - Pregnancy testing: confirm absence of pregnancy before initiating therapy. - Monitor ovarian response: use ultrasound to assess follicular growth. - Thromboembolic risk: evaluate patient history of clotting disorders. - Allergy assessment: screen for hypersensitivity to gonadotropins. - Dosage adjustment: modify based on hormonal monitoring and clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications that affect hormonal pathways or coagulation.

Major Interactions (Avoid): - GnRH antagonists: may blunt the effect of LH/FSH. - High‑estrogen contraceptives: can interfere with intended ovarian stimulation. - Anticoagulants: increased risk of bleeding at the injection site.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect metabolic clearance of gonadotropins. - Steroid hormones: may alter response to LH/FSH. - Diabetes medications: monitor glucose as hormonal changes can affect metabolism.